| Drugs by Condition |  |
Prostate Cancer
Definition: Prostate cancer involves a malignant tumor growth within the prostate gland.
Drugs (by generic name) associated with Prostate Cancer
The following drugs and medications are in some way related to, or used in the treatment of Prostate Cancer.
This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Prostate Cancer Related Drugs in the Pipeline
Provenge (sipuleucel-T)
- July 30, 2007
D.C. Denies Prostate Cancer Vaccine, Provenge: Dendreon (WA) Not FDA To Blame - June 1, 2007
Prostate Cancer Patients, Survivors and Advocates Assemble on Capitol Hill to Rally against FDA's Non Approval of Provenge - May 31, 2007
Dendreon Announces FDA Confirms Data Required for Provenge Licensure - May 9, 2007
Dendreon Receives Complete Response Letter From FDA for Provenge Biologics License Application - March 30, 2007
Dendreon Announces FDA Advisory Committee Reviewed Provenge for Hormone Refractory Prostate Cancer - March 27, 2007
Dendreon to Hold Post Advisory Committee Conference Call for Provenge - March 1, 2007
Dendreon Announces FDA's Cellular, Tissue and Gene Therapies Advisory Committee to Review Provenge for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer - January 16, 2007
Dendreon’s Provenge Granted FDA Priority Review - November 13, 2006
Dendreon Completes Submission of Biologics License Application to FDA for Provenge in Hormone Refractory Prostate Cancer - August 24, 2006
Dendreon Submits Clinical and Non-Clinical Sections of Rolling BLA to FDA for Provenge - September 14, 2005
Dendreon Announces Plans to Submit BLA
Satraplatin
- July 30, 2007
GPC Biotech Withdraws Satraplatin NDA for Accelerated Approval; Plans to Resubmit With Survival Analysis - July 25, 2007
Oncologic Drugs Advisory Committee Recommends FDA Wait for Overall Survival Analysis of Satraplatin for Treatment of Hormone-Refractory Prostate Cancer - May 15, 2007
Spectrum Pharmaceuticals Announces FDA'S Oncology Drug Advisory Committee to Review Satraplatin for the Treatment of Hormone Refractory Prostate Cancer - April 16, 2007
FDA Accepts GPC Biotech's Satraplatin NDA for Filing and Grants Priority Review Status - February 16, 2007
GPC Biotech Submits NDA for Lead Oncology Drug Candidate Satraplatin - July 12, 2006
GPC Biotech Submits Non-Clinical Section of Rolling NDA for Satraplatin - December 15, 2005
GPC Biotech Begins Rolling NDA Submission for Lead Drug Candidate Satraplatin
Xinlay (atrasentan)
- September 13, 2005
FDA Advisory Committee Does Not Recommend Approval of Xinlay (atrasentan) - February 11, 2005
FDA Agrees to File Abbott's New Drug Application for Xinlay (Atrasentan) to Treat Metastatic Hormone-Refractory Prostate Cancer - December 14, 2004
Abbott Submits New Drug Application to U.S. FDA for Advanced Prostate Cancer Drug, Xinlay (atrasentan)
Learn more about Prostate Cancer
Medical encyclopedia results for:
